Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Get Rating) Director Martin Joseph Joyce bought 4,323 shares of the company’s stock in a transaction dated Thursday, June 23rd. The shares were purchased at an average cost of $3.48 per share, with a total value of $15,044.04. Following the acquisition, the director now directly owns 23,967 shares of the company’s stock, valued at approximately $83,405.16. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
NASDAQ:ALDX opened at $3.68 on Monday. The business’s 50-day moving average price is $3.13 and its two-hundred day moving average price is $3.89. Aldeyra Therapeutics, Inc has a twelve month low of $2.36 and a twelve month high of $12.01. The stock has a market cap of $214.55 million, a P/E ratio of -3.32 and a beta of 1.64. The company has a quick ratio of 13.60, a current ratio of 13.60 and a debt-to-equity ratio of 0.08.
Aldeyra Therapeutics (NASDAQ:ALDX – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.02. During the same period in the previous year, the firm posted ($0.25) earnings per share. On average, equities research analysts expect that Aldeyra Therapeutics, Inc will post -1.37 EPS for the current fiscal year.
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
A number of research firms recently commented on ALDX. Berenberg Bank initiated coverage on Aldeyra Therapeutics in a research note on Tuesday, May 24th. They issued a “buy” rating and a $28.00 price target for the company. StockNews.com started coverage on Aldeyra Therapeutics in a report on Thursday, March 31st. They set a “sell” rating on the stock. Oppenheimer upped their target price on Aldeyra Therapeutics to $11.00 in a report on Thursday, June 9th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Aldeyra Therapeutics in a research report on Wednesday, April 27th. Finally, Citigroup upped their price objective on Aldeyra Therapeutics from $21.00 to $26.00 and gave the company a “buy” rating in a research note on Thursday, June 9th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Aldeyra Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $19.00.
Several large investors have recently added to or reduced their stakes in ALDX. Point72 Hong Kong Ltd purchased a new stake in shares of Aldeyra Therapeutics in the 4th quarter valued at about $31,000. ProShare Advisors LLC purchased a new position in shares of Aldeyra Therapeutics during the 4th quarter valued at about $43,000. Kestra Advisory Services LLC raised its holdings in shares of Aldeyra Therapeutics by 33.4% during the 4th quarter. Kestra Advisory Services LLC now owns 16,809 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 4,212 shares in the last quarter. PDT Partners LLC purchased a new position in shares of Aldeyra Therapeutics during the 1st quarter valued at about $82,000. Finally, Virtus ETF Advisers LLC raised its holdings in shares of Aldeyra Therapeutics by 40.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 24,298 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 7,002 shares in the last quarter. 62.94% of the stock is currently owned by hedge funds and other institutional investors.
Aldeyra Therapeutics Company Profile (Get Rating)
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Aldeyra Therapeutics right now?
Before you consider Aldeyra Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Aldeyra Therapeutics wasn’t on the list.
While Aldeyra Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Leave a Comment